Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Q3 results

- PMLiVE

AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement

RQ BIO has developed a portfolio of early-stage monoclonal antibodies targeting SARS-CoV-2

- PMLiVE

Eli Lilly and Incyte’s Olumiant approved by FDA for hospitalised COVID-19 patients

Nearly one million people with COVID-19 have been treated with Olumiant in approximately 15 countries worldwide

- PMLiVE

UK trial of fourth vaccine dose shows increased protection against COVID-19

The results of the study showed the booster vaccine was particularly effective in those over 70

- PMLiVE

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment

The licence application for the treatment of mild cognitive impairment due to Alzheimer’s disease was made as part of the accelerated approval pathway programme

- PMLiVE

WHO releases estimates of 14.9 million excess deaths during COVID-19 pandemic

The estimates show the full death toll caused directly or indirectly by the COVID-19 pandemic between 1 January 2020 and 31 December 2021

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy accepted for Priority Review in the US

The drug combination offers biliary tract cancer patients a new treatment option

- PMLiVE

FDA limits use of Janssen’s COVID-19 vaccine

Authorisation of Janssen COVID-19 vaccine restricted among certain people following analysis and evaluation

- PMLiVE

STORM Therapeutics receives Innovate UK grant

The grant will be used to research and develop a new coronavirus therapy

- PMLiVE

FDA grants Prothena fast-track designation for next-generation Alzheimer’s disease therapy

Approximately 50 million people worldwide are estimated to be living with Alzheimer’s disease or other dementias

- PMLiVE

FDA approves Alexion’s Ultomiris for generalised myasthenia gravis

gMG is a rare autoimmune neuromuscular disease that causes a loss of muscle function and severe weakness

- PMLiVE

FDA approves COVID-19 treatment for those under the age of 12

Veklury is currently the only COVID-19 treatment approved for this age group

- PMLiVE

Gilead’s Veklury significant decreases risk of hospitalisation for COVID-19 patients

Using Veklury within five days of symptom onset – or between five to seven days of symptom onset – reduced hospitalisations in patients at high risk for severe COVID-19 disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links